文献速递甲状腺与颈部外科围术期管理与 ERAS

原发性甲状旁腺功能亢进症药物与手术联合治疗的骨骼效应

Skeletal effects of combined medical and surgical management of primary hyperparathyroidism.
PubMed 文献 · Surgery · 2019-09-30

本回顾性队列研究纳入1,737例骨质疏松合并原发性甲状旁腺功能亢进症患者,比较观察、单用双膦酸盐、单用甲状旁腺切除术(PTX)、先双膦酸盐后PTX、先PTX后双膦酸盐五组的骨折风险与髋部骨密度变化。结果显示PTX及先双膦酸盐后PTX与骨折风险降低相关,而先PTX后双膦酸盐及单用双膦酸盐的骨折风险与观察组相似。

要点

  • PTX与骨折风险降低相关(HR 0.55,95%CI 0.35-0.84)。
  • 先双膦酸盐后PTX亦与骨折风险降低相关(HR 0.46,95%CI 0.25-0.83)。
  • PTX后启用双膦酸盐可能干扰PTX对骨折风险的有益效应。

核心结论

  • 在骨质疏松合并原发性甲状旁腺功能亢进症患者中,PTX后启用双膦酸盐可能干扰PTX对骨折风险的有益效应。

研究设计与样本

  • 回顾性队列研究,纳入1995-2016年未使用过双膦酸盐的骨质疏松合并原发性甲状旁腺功能亢进症患者(钙>10.5 mg/dL;PTH>65)。
  • 采用时变Cox回归估计5个比较组(观察、单用双膦酸盐、单用PTX、先双膦酸盐后PTX、先PTX后双膦酸盐)的调整骨折风险。

主要发现

  • 队列共1,737例,其中303例(17%)行PTX,433例(25%)仅用双膦酸盐,125例(7%)先双膦酸盐后PTX,69例(4%)先PTX后双膦酸盐。
  • PTX与骨折风险降低相关(HR 0.55,95%CI 0.35-0.84),先双膦酸盐后PTX亦与骨折风险降低相关(HR 0.46,95%CI 0.25-0.83)。
  • 先PTX后双膦酸盐(HR 1.09,95%CI 0.65-1.81)及单用双膦酸盐(HR 0.82,95%CI 0.62-1.08)的骨折风险与观察组相似。
  • PTX后髋部骨密度增加5.50%(95%CI 3.39-7.61),先PTX后双膦酸盐后增加6.30%(95%CI 2.53-10.07)。

临床怎么用

  • 对于骨质疏松合并原发性甲状旁腺功能亢进症患者,PTX是降低骨折风险的有效选择。
  • 如需联合双膦酸盐,优先考虑在PTX前启用而非PTX后启用,以避免可能干扰PTX的骨骼获益。

局限性

  • 本研究为回顾性队列研究,可能存在选择偏倚和混杂因素。
  • 双膦酸盐使用时机及依从性等信息可能不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Parathyroidectomy (PTX) increases bone mineral density and decreases fracture risk in patients with primary hyperparathyroidism. This study examined the effect of adding bisphosphonates either before or after PTX on skeletal outcomes. METHODS: A retrospective cohort study of bisphosphonate-naïve patients (1995-2016) with osteoporosis and primary hyperparathyroidism (calcium >10.5 mg/dL; PTH >65) was performed. Time-varying Cox regression was used to estimate an adjusted risk of any fracture in 5 comparison groups: observation, bisphosphonates alone, PTX alone, bisphosphonates then PTX, and PTX then bisphosphonates. The secondary outcome was change in bone mineral density of the hip. RESULTS: The cohort comprised 1,737 patients, of whom 303 underwent PTX (17%), 433 received bisphosphonates only (25%), 125 had bisphosphonates then PTX (7%), and 69 had PTX then bisphosphonates (4%). PTX was associated with a decrease in fracture risk (HR 0.55, 95% CI 0.35-0.84), as was bisphosphonates then PTX (HR 0.46, 95% CI 0.25-0.83). In contrast, the fracture risks associated with PTX then bisphosphonates (HR 1.09, 95% CI 0.65-1.81) and bisphosphonates alone (HR 0.82, 95% CI 0.62-1.08) were similar to observation. Hip bone mineral density increased after both PTX (5.50%, 95% CI 3.39-7.61) and PTX then bisphosphonates (6.30%, 95% CI 2.53-10.07). CONCLUSION: Bisphosphonate initiation after PTX may interfere with the beneficial effects of PTX on fracture risk in osteoporotic patients with primary hyperparathyroidism.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Orr LE, Zhou H, Zhu CY, et al. Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery. 2019. PMID: 31582307. doi:10.1016/j.surg.2019.04.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。